Still Looking For The Off-The-Shelf Breakthrough, Allogene Touts Myeloma CAR-T Candidate

Raises Hopes Of Challenging Abecma And Carvykti

Allogene building
Allogene's CD19-targeting off-the-shelf CAR-Ts have hit setbacks, putting pressure on its multiple myeloma targeting candidates to succeed. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapy Areas